Excelsior Biopharma Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 187.88 million compared to TWD 155.31 million a year ago. Net loss was TWD 36.17 million compared to TWD 12.45 million a year ago. Basic loss per share from continuing operations was TWD 0.79 compared to TWD 0.27 a year ago. Diluted loss per share from continuing operations was TWD 0.79 compared to TWD 0.27 a year ago.
For the six months, sales was TWD 375.87 million compared to TWD 328.96 million a year ago. Net loss was TWD 60.09 million compared to TWD 22.57 million a year ago. Basic loss per share from continuing operations was TWD 1.31 compared to TWD 0.49 a year ago. Diluted loss per share from continuing operations was TWD 1.31 compared to TWD 0.49 a year ago.